These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. Drug-coated balloons vs. drug-eluting stents for treatment of long femoropopliteal lesions. Zeller T; Rastan A; Macharzina R; Tepe G; Kaspar M; Chavarria J; Beschorner U; Schwarzwälder U; Schwarz T; Noory E J Endovasc Ther; 2014 Jun; 21(3):359-68. PubMed ID: 24915582 [TBL] [Abstract][Full Text] [Related]
9. Intravascular ultrasound measurements after drug-eluting stent placement in femoropopliteal lesions: determining predictors of restenosis. Mori S; Hirano K; Nakano M; Muramatsu T; Tsukahara R; Ito Y; Ishimori H J Endovasc Ther; 2015 Jun; 22(3):341-9. PubMed ID: 25862363 [TBL] [Abstract][Full Text] [Related]
10. Real-World Performance of Paclitaxel Drug-Eluting Bare Metal Stenting (Zilver PTX) for the Treatment of Femoropopliteal Occlusive Disease. Tran K; Ullery BW; Kret MR; Lee JT Ann Vasc Surg; 2017 Jan; 38():90-98. PubMed ID: 27554688 [TBL] [Abstract][Full Text] [Related]
11. Paclitaxel-Eluting Balloon vs Standard Angioplasty to Reduce Restenosis in Diabetic Patients With In-Stent Restenosis of the Superficial Femoral and Proximal Popliteal Arteries: Three-Year Results of the DEBATE-ISR Study. Grotti S; Liistro F; Angioli P; Ducci K; Falsini G; Porto I; Ricci L; Ventoruzzo G; Turini F; Bellandi G; Bolognese L J Endovasc Ther; 2016 Feb; 23(1):52-7. PubMed ID: 26511896 [TBL] [Abstract][Full Text] [Related]
13. Mid-Term Outcomes of Endovascular Treatment for TASC-II D Femoropopliteal Occlusive Disease with Critical Limb Ischemia. Torres-Blanco Á; Edo-Fleta G; Gómez-Palonés F; Molina-Nácher V; Ortiz-Monzón E Cardiovasc Intervent Radiol; 2016 Mar; 39(3):344-52. PubMed ID: 26202389 [TBL] [Abstract][Full Text] [Related]
14. Newly approved devices for endovascular treatment of femoropopliteal disease: a review of clinical evidence. Giannopoulos S; Armstrong EJ Expert Rev Cardiovasc Ther; 2019 Oct; 17(10):729-740. PubMed ID: 31575289 [No Abstract] [Full Text] [Related]
15. Randomized comparison of femoropopliteal artery drug-eluting balloons and drug-eluting stents (FOREST trial): Study protocol for a randomized controlled trial. Jongsma H; van Mierlo-van den Broek P; Imani F; van den Heuvel D; de Vries JPM; Fioole B J Vasc Surg; 2017 Oct; 66(4):1293-1298. PubMed ID: 28826727 [TBL] [Abstract][Full Text] [Related]
16. Comparison of Drug-Eluting Stent with Bare-Metal Stent Implantation in Femoropopliteal Artery Disease: A Systematic Review and Meta-Analysis. Ding Y; Zhou M; Wang Y; Cai L; Shi Z Ann Vasc Surg; 2018 Jul; 50():96-105. PubMed ID: 29514049 [TBL] [Abstract][Full Text] [Related]
17. Drug-coated balloon angioplasty for in-stent restenosis of femoropopliteal arteries: a meta-analysis. Cassese S; Ndrepepa G; Kufner S; Byrne RA; Giacoppo D; Ott I; Laugwitz KL; Schunkert H; Kastrati A; Fusaro M EuroIntervention; 2017 Jul; 13(4):483-489. PubMed ID: 28169215 [TBL] [Abstract][Full Text] [Related]
18. Drug-Eluting Stent vs Percutaneous Transluminal Angioplasty for Treatment of Femoropopliteal In-Stent Restenosis: Results From a Retrospective 1-Year Multicenter Study. Murata N; Takahara M; Soga Y; Nakano M; Yamauchi Y; Zen K; Kawasaki D; Yokoi H; Tosaka A; Tanaka N; Iida O J Endovasc Ther; 2016 Aug; 23(4):642-7. PubMed ID: 27099284 [TBL] [Abstract][Full Text] [Related]
19. Drug-eluting stenting for femoropopliteal lesions, followed by cilostazol treatment, reduces stent restenosis in patients with symptomatic peripheral artery disease. Zen K; Takahara M; Iida O; Soga Y; Kawasaki D; Nanto S; Yokoi H; Matoba S; J Vasc Surg; 2017 Mar; 65(3):720-725. PubMed ID: 28073668 [TBL] [Abstract][Full Text] [Related]
20. Eluvia drug-eluting vascular stent system for the treatment of symptomatic femoropopliteal lesions. Müller-Hülsbeck S; Hopf-Jensen S; Keirse K; Zeller T; Schroë H; Diaz-Cartelle J; Gray WA Future Cardiol; 2018 May; 14(3):207-213. PubMed ID: 29631434 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]